Your browser doesn't support javascript.
loading
Accuracy of plasma Aß40, Aß42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform.
Martínez-Dubarbie, Francisco; Guerra-Ruiz, Armando; López-García, Sara; Lage, Carmen; Fernández-Matarrubia, Marta; Infante, Jon; Pozueta-Cantudo, Ana; García-Martínez, María; Corrales-Pardo, Andrea; Bravo, María; López-Hoyos, Marcos; Irure-Ventura, Juan; Sánchez-Juan, Pascual; García-Unzueta, María Teresa; Rodríguez-Rodríguez, Eloy.
Afiliación
  • Martínez-Dubarbie F; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain. dubarmar@hotmail.com.
  • Guerra-Ruiz A; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, 39011, Spain. dubarmar@hotmail.com.
  • López-García S; Biochemistry and Clinical Analysis Department, Marqués de Valdecilla University Hospital, Santander, Cantabria, 39008, Spain.
  • Lage C; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain.
  • Fernández-Matarrubia M; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, 39011, Spain.
  • Infante J; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain.
  • Pozueta-Cantudo A; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, 39011, Spain.
  • García-Martínez M; Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute, University of California, San Francisco, San Francisco, USA.
  • Corrales-Pardo A; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain.
  • Bravo M; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, 39011, Spain.
  • López-Hoyos M; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain.
  • Irure-Ventura J; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, 39011, Spain.
  • Sánchez-Juan P; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, 28220, Spain.
  • García-Unzueta MT; Medicine and Psychiatry Department, University of Cantabria, Santander, Spain.
  • Rodríguez-Rodríguez E; Neurology Service, Marqués de Valdecilla University Hospital, Avda. de Valdecilla 25, Santander, Cantabria, 39008, Spain.
Alzheimers Res Ther ; 15(1): 163, 2023 10 02.
Article en En | MEDLINE | ID: mdl-37784138
ABSTRACT

BACKGROUND:

The arrival of new disease-modifying treatments for Alzheimer's disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Plasma markers of AD are very promising, but it is necessary to prove that alterations in their levels are related to alterations in gold standard markers such as cerebrospinal fluid or PET imaging. With this research, we want to evaluate the performance of plasma Aß40, Aß42, and p-tau181 to detect the pathological changes in CSF using the automated Lumipulse platform.

METHODS:

Both plasma and CSF Aß40, Aß42, and p-tau181 have been evaluated in a group of 208 cognitively unimpaired subjects with a 30.3% of ApoE4 carriers. We have correlated plasma and CSF values of each biomarker. Then, we have also assessed the differences in plasma marker values according to amyloid status (A - / +), AD status (considering AD + subjects to those A + plus Tau +), and ATN group defined by CSF. Finally, ROC curves have been performed, and the area under the curve has been measured using amyloid status and AD status as an outcome and different combinations of plasma markers as predictors.

RESULTS:

Aß42, amyloid ratio, p-tau181, and p-tau181/Aß42 ratio correlated significantly between plasma and CSF. For these markers, the levels were significantly different in the A + / - , AD + / - , and ATN groups. Amyloid ratio predicts amyloid and AD pathology in CSF with an AUC of 0.89.

CONCLUSIONS:

Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer's pathology in cognitively unimpaired subjects.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article País de afiliación: España